Searched for
UMIFENOVIR
Are fundamental tailwinds a stronger play than volatile markets? 6 mid-cap pharma stocks with an upside potential of over 22%The Indian pharmaceutical sector has undergone significant changes over the past decade, marking a transition from a period of consolidatio...- Mid-cap pharma space: Risk & opportunity are two sides of the same coin. 7 pharma stocks with upside potential of up to 41%Two things increase the probability of a sector becoming the next big sector in India. One: As a country, India should have some edge in th...
- Volatile phases come and go, structural tailwinds are a stronger play: 5 Indian pharma stocks with upside potential of up to 35%There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did ...
- Medicine for bearish markets: 5 Indian pharma stocks with upside potential of up to 32%There are some sectors which are able to face bears in a better way. The reason, the operating matrix of those sectors is such that rising ...
- Second & better attempt; 5 Indian pharma stocks with upside potential of up to 31%Both, in terms of bottomline and stock price performance, pharma stocks had been under pressure for a long time. Partly this under performa...
- After a long winter finally some tailwinds; 6 pharma stocks with upside potential of up to 31%While all pharma companies get classified into one sector they are very different at molecular level. Each company has its own operating ma...
- A Healthy Dose! 4 midcap pharma stocks with upside potential of up to 36%After a long period of under performance, pharma stocks have seen interest coming back from institutional investors. This is because some t...
- Finally out of the woods? 4 midcap pharma stocks with an upside potential up to 34 %Pharma stocks had been underperforming for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets h...
- On a path to recovery: 5 midcap pharma stocks with an upside potential up to 32%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are mid-sized In...
- On a path to recovery; 5 mid-cap pharma stocks with an upside potential up to 41%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in bearish markets. Some of them are mid-sized Ind...
- 6 midcaps that have beaten bearish & volatile markets can rise up to 42%, suggest analystsOnce again the US banks are at the center of a storm in equity markets. In such times, a few mid-cap stocks have been able to keep their he...
- Midcaps with long term perspective; 9 stocks with high ROE & net profit marginMany investors, especially the ones sitting on cash are confused about what they should do with their existing stocks – buy the dip or not....
- On a path to recovery; 7 mid-cap pharma stocks with an upside potential up to 47 %After the covid tailwinds got over, pharma stocks witnessed a phase of under-performance. However as the markets get jittery, select pharma...
- No 'significant' benefit of favipiravir, umifenovir combination in Covid treatment: GlenmarkGlenmark had in May intimated the study to examine whether early administration of a combination of Favipiravir and Umifenovir enhances ant...
- Drug firms get DGCI nod for Covid drug favipiravir despite inconclusive studyOn Tuesday, Hyderabad-based Biophore India Pharmaceuticals said it has received approval from the Drug Controller General of India (DGCI) t...
- Glenmark Pharma cuts price of COVID-19 drug by 27% to Rs 75 per tabletIn a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab...
- Glenmark launches COVID-19 drug after DCGI nod; MRP at Rs 103 per tabletThe company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer p...
- COVID-19: CSIR institute to conduct clinical trials of antiviral drug UmifenovirThe drug has a good safety profile and acts by preventing entry of viruses into human cells and also by priming the immune system, accordin...
- Lockdown, Day 63: India faces volley of shotsIndia is facing a volley of shots from all fronts as growth forecast is plummeting, and India faces a resurgent Chinese army at Ladakh. The...
- Glenmark Pharma to study potential Covid-19 drug combinationThe study will look to enroll 158 hospitalized patients of moderate Covid-19 in India, the company added. Last month, Glenmark said it woul...
Load More
